3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
pembrolizumab
4
Pemetrexed
3
Paclitaxel
3
Fulvestrant
2
FANG vaccine
2
Drug Therapy
2
Carboplatin
2
tucatinib
1
trastuzumab deruxtecan
1
seribantumab
1
selinexor
1
osimertinib
1
gedatolisib
1
dactolisib
1
cobimetinib
1
cemiplimab
1
atezolizumab
1
Watchful Waiting
1
Trastuzumab
1
Transurethral Resection of Prostate
1
Trabectedin
1
Therapeutics
1
Sutures
1
Radiation
1
Quality of Life
1
Pregnancy Tests
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
OSI 930
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Uterine Neoplasms
×
Pregnancy Tests
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled